Navigation Links
Bend Research Signs Technology Licensing Agreement with Merck
Date:11/14/2011

BEND, Ore., Nov. 14, 2011 /PRNewswire/ -- Bend Research Inc. (www.bendresearch.com), a leading independent drug-formulation development and manufacturing company, announced today that it has entered into a licensing agreement with Merck, through a subsidiary.

Under the terms of the agreement, Bend Research will provide Merck access to its proprietary spray-dried dispersion (SDD) technology. Depending on Merck's additional needs, Bend may also provide Merck with access under the license agreement to additional drug-delivery platforms and intellectual property, including modified-release technologies and drug-discovery formulation tools.

Under the collaboration, the two companies hope to use their complementary fundamental scientific and engineering capabilities to solve complex formulation and process-development problems with an eye toward transferring these solutions to a cGMP environment.

"We are excited to extend our working relationship with Merck," said Rod Ray, Chief Executive Officer of Bend Research. "Building stronger collaborative relationships with leading companies like Merck is important to Bend Research's future. This relationship expands our opportunities to deliver best-in-class medicines and fits well with Merck's mission to help provide innovative products that save and improve people's lives."

About Bend Research Inc.

For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.

Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical-trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. Bend Research is a leader in novel formulations, including solubilization technologies such as SDDs and hot-melt extrusion formulations, as well as controlled-release, inhalation, and biotherapeutics technologies.

Bend Research has more than 240 employees based in four state-of-the-art facilities in Bend, Ore., USA.


'/>"/>
SOURCE Bend Research Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
2. New Research Suggests That Acthar Reduces Proteinuria in Idiopathic Membranous Nephropathy In Part Through Suppression of Anti-PLA2R Antibodies
3. Millar Instruments, Inc. and Telemetry Research Ltd Merge
4. Transparency Market Research: The North America and Europe Minimally Invasive Prostate Cancer Surgery Market is Booming: Expected to Attain a Market Size of USD 24.9 Billion by 2016
5. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
6. Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting
7. SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
8. Critical Alerts For Barrick Gold, Molycorp, Lockheed Martin, Teva Pharmaceutical, and Tenaris Released By Seven Summits Research
9. Kensey Nash Corporation Receives $1.9m NIH Grant for Tendon Product Research
10. Caliper Launches New Platform for Drug Safety Prediction and Oncology Research
11. JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):